Genetic polymorphism of CYP2D6 in Chinese subjects in Malaysia

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 4, 2003, Pages 279-284

  Ismail, Rusli ^a   K Teh, L ^a   Amir, J ^a   Alwi, Z ^a   Lopez, C G ^b  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Allele frequency; CYP2D6 polymorphism; Ethnic difference; Malaysian Chinese

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CYP2D6 GENE; DNA DETERMINATION; DNA POLYMORPHISM; ETHNIC DIFFERENCE; EVOLUTION; GENE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHY; HUMAN; HUMAN CELL; MALAYSIA; METABOLISM; PHENOTYPE; POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENOTYPE; HUMANS; MALAYSIA; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 0042380030     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00490.x     Document Type: Article

References (28)

1. Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. Clinical Pharmacokinetics, 29, 192-209.
2. Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR (2001) Heterogeneity of the CYP2D6 gene among Malays in Malaysia. Journal of Clinical Pharmacology and Therapeutics, 26, 1-7.
3. Ismail R, Teh LK (2001) Genetic polymorphism of CYP2D6: Malaysian Indians have the highest frequency for CYP2D6*4 in Asia. European Journal of Clinical Pharmacology, 57, 617-618.
4. Heim M, Meyer UA (1990) Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529-532.
5. Tyndale R, Aoyama T, Borly F et al. (1991) Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics, 1, 26-32.
6. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics, 7, 187-191.
7. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Molecular Pharmacology, 46, 452-459.
8. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M (1996) A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. British Journal of Clinical Pharmacology, 42, 713-719.
9. Lundqvist E, Johansson I and Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene, 226, 327-338.
10. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of the poor metabolizer-associated I(D) gene deletion allele by long PCR technology. Pharmacogenetics, 5, 215-223.
11. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics, 38, 402-408.
12. Lee EJ, Yeoh PN, Hee GN (1988) Oxidation phenotyping in Chinese and Malay populations. Clinical and Experimental Pharmacology and Physiology, 15, 889-891.
13. Bertilsson L, Lou YQ, Du YL et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clincal Pharmacology and Therapeutics, 51, 388-397.
14. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, Bertilsson L (1995) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics, 5, 159-164.
15. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics, 6, 441-447.
16. Tateishi T, Chiba M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clinical Pharmacology and Therapeutics, 65, 570-575.
17. Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, Waye MM (2000) Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clinical Chemistry, 46, 18-23.
18. Lee EJ, Jeyaseelan K (1994) Frequency of human CYP2D6 mutant alleles in a normal Chinese population. British Journal of Clinical Pharmacology, 37, 605-607.
19. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clinical Pharmacology and Therapeutics, 53, 410-418.
20. Du YL, Lou YQ (1990) Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population. Chung Kuo Yao Li Hsueh Pao, 11, 7-10.
21. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. British Journal of Clinical Pharmacology, 50, 31-34.
22. Yokota H, Tamura S, Furuya H et al. (1993). Evidence of a new variant allele CYP2D6J in a Japanese population associated with lower in vivo rates of spartein metabolism. Pharmacogenetics, 3, 256-263.
23. Armstrong M, Fairbrother K, Idle JR, Daly AK (1994) The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics, 4, 73-81.
24. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proceedings of the National Academy of Sciences of the United States of America, 90, 11825-11829.
25. Shaw GL, Weiffenbach B, Falk RT, Frame JN, Issaq HJ, Moir DT, Caporaso N (1997) Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls. Lung Cancer, 17, 61-68.
26. Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics, 9, 715-723.
27. Wennerholm A, Johansson I, Massele AY et al. (1999) Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics, 9, 707-714.
28. Marez D, Legrand M, Sabbagh N et al. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics, 7, 193-202.